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Abstract
West Nile virus (WNV) is a mosquito-borne member of flaviviruses that causes significant
morbidity and mortality especially among children. There is currently no approved vaccine or
antiviral therapeutic for human use. In a previous study, we described compounds containing the
8-hydroxyquinoline (8-HQ) scaffold as inhibitors of West Nile virus serine protease (NS2B/
NS3pro) in a high throughput screen (HTS) using the purified WNV NS2B/NS3pro as the target.
In this study, we analyzed potencies of some commercially available as well as chemically
synthesized derivatives of 8-HQ by biochemical assays. An insight into the contribution of various
substitutions of 8-HQ moiety for inhibition of the protease activity was revealed. Most
importantly, the substitution of the N1 of the 8-HQ ring by –CH– in compound 26 significantly
reduced the inhibition of the viral protease by this naphthalen-1-ol derivative. The kinetic constant
(Ki) for the most potent 8-HQ inhibitor (compound 14) with an IC50 value of 2.01 ± 0.08 μM
using the tetra-peptide substrate was determined to be 5.8 μM. This compound inhibits the WNV
NS2B/NS3pro by a competitive mode of inhibition which is supported by molecular modeling.
1. Introduction
West Nile virus, a member of mosquito-borne Flaviviridae family, belongs to the Japanese
encephalitis serocomplex which includes Japanese encephalitis virus, West Nile virus
(WNV), Kunjin virus, and Murray Valley encephalitis virus. WNV causes significant
morbidity and mortality (for reviews, see Brinton (2002); Gould and Solomon (2008),
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Lindenbach and Rice (2003) and Weaver and Barrett (2004). WNV was previously
unknown in the U.S. In 1999, the first epidemic of WNV occurred in New York City. Since
then reported cases of WNV spread to most of the U.S. by infection cycle between certain
species of mosquitoes and bird species serving as reservoirs. Because
human→mosquito→human transmission cycle does not occur, humans are considered as
dead-end hosts. Most WNV infections are either asymptomatic or associated with mild flu-
like symptoms, which could, in a small number of cases, advance to encephalitis (Gould and
Solomon, 2008). There are currently no vaccines or antiviral therapeutics available for
treatment of WNV-infected patients.
WNV encodes a positive-strand RNA of about 11 kb in length that is translated to a single
polyprotein precursor which produces 10 mature proteins by co- and post-translational
processing. The three proteins, the capsid (C), precursor/mature membrane protein (prM/M),
and the envelope (E) form the virion; the seven nonstructural proteins (NS1, NS2A, NS2B,
NS3, NS4A, NS4B, and NS5) are expressed in the infected cells and are required for viral
replication (for reviews, see (Beasley, 2005; Lindenbach and Rice, 2003)).
The two component viral serine protease, NS2B-NS3, plays a crucial role in viral replication
as it is required for processing of the polyprotein precursor prior to the assembly of the viral
replicase complex. This requirement makes the viral protease an excellent target for
development of antiviral therapeutics. The viral protease cleavage sites have in common a
pair of basic amino acids, R and K, (or Q at the P2 position of DENV2 NS2B-NS3 cleavage
site) followed by G, S, or A at the P1′ position (Lindenbach and Rice, 2003) (according to
the nomenclature of (Schechter and Berger, 1967)). The serine protease catalytic triad is
located within the N-terminal 185 amino acids (Bazan and Fletterick, 1989; Chambers et al.,
1990; Preugschat et al., 1990). NS2B is the required cofactor for NS3 protease activity
(Chambers et al., 1991; Falgout et al., 1991; Wengler et al., 1991; Zhang et al., 1992). The
NS2B is an integral membrane protein in the endoplasmic reticulum (Clum et al., 1997)
containing hydrophobic regions flanking a hydrophilic region of ~45 amino acid residues
which forms a complex with the NS3 protease domain (Arias et al., 1993; Chambers et al.,
1993; Clum et al., 1997; Falgout et al., 1993). Using an E. coli-expressed and purified
DENV2 NS2B/NS3pro, an in vitro protease assay using a fluorogenic tri-peptide substrate
was established. This assay demonstrated that NS2B stimulates the protease activity of the
NS3pro domain ~3300-fold with the Boc-G-R-R-7-amino-4-methyl coumarin (AMC)
substrate (Yusof et al., 2000). Subsequent studies optimized the expression levels, solubility
and catalytic properties of the DENV2 and WNV NS2B-NS3 proteases (Leung et al., 2001;
Li et al., 2005; Nall et al., 2004; Shiryaev et al., 2007). The crystal structures of the WNV
NS2B-NS3 protease complex containing a covalently bound tetra-peptide substrate-based
inhibitor (Erbel et al., 2006) or a non-covalent complex with the trypsin inhibitor, aprotinin
(Aleshin et al., 2007) have been solved. Similarly, the crystal structures of DENV2 (Erbel et
al., 2006), DENV1 (Chandramouli et al., 2010) and WNV NS2B/NS3pro (Aleshin et al.,
2007) in the absence of a substrate-based inhibitor have also been solved. These studies
provide information regarding the substrate specificity as well as the role of cofactor NS2B
peptide in activation of the NS3pro domain.
In a previous study, we reported the adaptation of the in vitro WNV protease assay with the
tri-peptide substrate, Boc-G-K-R-AMC to a high throughput screening (HTS) format. We
screened ~32,000 compounds and identified 98 compounds with several distinct chemical
scaffolds. One group of these compounds contained an 8-HQ moiety as a common scaffold.
In this study, we analyzed some commercially available as well as chemically synthesized
derivatives of 8-HQ including one compound in which 8-HQ was replaced with a
naphthalen-1-ol ring.
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2. Materials and Methods
2.1 Materials
The WNV NS2B-NS3pro expression plasmid encoding the protease precursor used in this
study contains the hydrophilic domain of NS2B cofactor (45 amino acids) and the NS3pro
domain (186 residues + 2 residues LN from HindIII site at the C-terminus of NS3pro)
separated by five C-terminal amino acids (QYTKR↓) of NS2B (P1 to P5). The expression
and purification of this protease has been described previously (Mueller et al., 2007, 2008).
The WNV NS2B-NS3 protease precursor underwent autoproteolysis at KR↓ to yield a non-
covalently associated NS2B/NS3pro complex which was purified by TalonR affinity matrix
(Clontech) (Mueller et al., 2007). The fluorogenic peptide substrates, t-butyl-oxycarbonyl
(Boc)-Gly-Lys-Arg-7-amino-4-methyl coumarin (AMC) and Benzoyl (Bz)-norleucine
(Nle)-Lys-Arg-Arg-AMC were purchased from Bachem (Torrance, CA). For later
experiments, Bz-Nle-Lys-Arg-Arg-AMC was also custom-synthesized by NeoBioScience
(Cambridge, MA). AMC was purchased from Anaspec, Inc (Fremont, CA). The 8-HQ
compounds with codes (molecular weights and ID numbers within parentheses) are: 10
(M.W. 357.41; T0511-7984), 13 (M.W. 383.47; LT00013768), compound B (M.W. 349.41;
T0510-2459; ref. (Mueller et al., 2008)) were purchased from Ryan Scientific Inc., Mt.
Pleasant, S.C. The following compounds with IDs, II-11-, series were synthesized by Dr.
Kyungae Lee: 14 (M.W. 439.53; II-11-1), 15 (M.W. 347.43; II-11-2), 16 (447.53; II-11-3),
17 (M.W. 489.59; II-11-5), 18 (M.W. 438.54; II-11-6), 19 (M.W. 453.56; II-11-7), 20
(M.W. 349.41; II-11-10), 21 (M.W. 363.43; II-11-13), 22 (M.W. 398.48; II-11-11), 23
(M.W. 333.41; 7211190047), 24 (M.W. 323.37; 7211800112), 25 (M.W. 334.39; II-11-4),
26 (M.W. 396.48; II-26-3). Compounds 20 (T0508-1930) and 23 (F0870-0049) were re-
purchased from Ryan Scientific Inc. Compound 14 was re-synthesized by Dr. Huiguo Lai
and it was found to be at least 98% pure as analyzed by NMR.
2.2. In vitro protease assays
All assays were done in triplicate in black 96-well plates. Protease activity experiments were
performed in vitro using purified viral protease NS2B-NS3-pro from WNV. The reaction
mixture of 100 μL/well contained 200 mM Tris pH 9.5, 30% glycerol, 27 nM WNV, 2%
DMSO and fluorogenic WNV substrate Boc-GKR-AMC at 100 μM for percent inhibition
experiments as indicated. To validate the assay conditions, aprotinin (bovine pancreatic
trypsin inhibitor, BPTI) was used as a positive control (Ki for WNV NS2B/NS3pro ≈ 162
nM at a final concentration of 2–10 μM. Assay mixtures containing 2% dimethyl sulfoxide
(DMSO) were used for the no-inhibitor control. Furthermore, a control containing only 2%
DMSO and the substrate was used to achieve the minimum value of relative fluorescence
units (RFU) for background subtraction. In all assays, the inhibitor-enzyme complex was
allowed to form by pre-incubation for 15 min at room temperature (RT) before addition of
the substrate. After 5 min incubation, reactions were monitored by the release of free AMC,
every 1.5 min for 30 min. The fluorescence emission was recorded at 465 nm following
excitation at 385 nm using the SpectraMax Gemini EM (Molecular Devices). The relative
fluorescence units (RFU) were converted to absolute AMC product concentrations using
Excel, where the data were transformed using the slope from the linear regression of the
AMC calibration curve generated from the fluorescence values versus micromolar (μM)
concentrations of free AMC. RFUs, obtained in a standard assay in the absence of inhibitors,
were taken as 100% protease activity (or 0% inhibition), the background value (no protease)
as 0% activity (or 100% inhibition).
2.3. Determination of IC50
To determine the 50% inhibitory concentration (IC50) of a compound, protease assays were
performed as described above except in the presence of various concentrations of an
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inhibitor (0.3 – 40 μM), serially diluted in 100% DMSO. The final DMSO concentration
was 2% in each well. RFU values were converted into percent inhibition. The data were
fitted to a sigmoid dose-response function using non-linear regression analysis of GraphPad
Prism 5 and IC50 values were obtained. The IC50 values were also determined using the
tetra-peptide substrate in the range of 5 nM to 25 μM as described in the text.
2.4. Kinetic analysis
To determine the Km and Vmax values of compound 14, four different concentrations of the
inhibitor (0 to 5 μM) were assayed at twelve tetra-peptide substrate concentrations ranging
from 0–50 μM. Ki value was calculated from these data using SigmaPlot.
2.5. Molecular docking of compounds 14, 17, 18, 22 and 26 into WNV protease
Compounds 14, 17, 18, 22 and 26 were sketched in ZINC (UCSF) and converted to
SMILES strings (http://zinc.docking.org/choose.shtml). The NCI/CADD Group SMILES
Translator and Structure File Generator Molecular (http://cactus.nci.nih.gov/translate/) was
used to generate coordinates in the .mol2 format. AutoDockTools was used to add hydrogen
atoms and electric charges. Molecular docking was performed using AutoDock Vina
(http://mgltools.scripps.edu) implementing grid-based scoring. Each compound was docked
in 1,000 orientations and the best scoring orientations were energy-minimized.
3. Results and Discussion
3.1. Inhibition of WNV NS2B/NS3pro by 8-HQ derivatives
In our previous study, we reported identification of small molecule inhibitors of WNV
NS2B/NS3pro using a fluorogenic tri-peptide substrate, Boc-G-K-R-AMC, in a high
throughput screening initiative. The 98 compounds selected as primary “hits” with drug-like
physicochemical and pharmacological properties were divided into five groups based on
structural similarity. Two groups of compounds are substituted at position 7 of the 8-HQ
ring (R1) and are linked to either an –NH–C=O or an –NH– group (Mueller et al., 2008).
The lead compound B, a 8-HQ derivative belonging to the –NH– group, was reported to
have a Ki value of 3.4 ± 0.6 μM (Mueller et al., 2008). In this study, fifteen 8-HQ
compounds including the compound B having the 8-HQ scaffold (Fig. 1) and one additional
compound (compound 26) containing a naphthalen-1-ol instead of the 8-HQ scaffold were
characterized for their percent inhibition of WNV NS2B/NS3pro in order to develop a
structure-activity relationship and mode of inhibition.
The in vitro protease assays were performed using the WNV protease NS2B/NS3-pro and
the tri-peptide substrate in the absence or the presence of an inhibitor at a fixed
concentration of 40 μM. Eight compounds and the compound B, characterized previously as
a lead inhibitor of WNV NS2B/NS3pro (Mueller et al., 2008) showed ≥ 70% inhibition
(Fig. 2). It is noteworthy that compound 26 containing the naphthalen-1-ol scaffold with the
substitution of N1 of 8-HQ with –CH–, reduced the inhibitory activity of compound 22 from
~99% to 26% (discussed further below). These results indicated that the 8-HQ moiety is a
major determinant for inhibition of WNV NS2B/NS3pro by this class of compounds. In
compounds 15 and 18, addition of a methyl group, even in the para position of the –CH–, or
a benzyloxy (–OBn) group in the ortho position in R2 (Fig. 1) inhibited the protease activity
by ~60% and 20%, respectively. Comparison of the activities of compounds 18, 20, 21 and
23 indicate that either no substitution or the position of the benzyl ring substitution in R2 is
an important determinant for inhibition of WNV protease. Substitution in the ortho position
to the –CH– in the R2 tends to interfere with the inhibitory activity of the compounds,
perhaps due to steric hindrance in which –OH seems to be more favorable than -OBn, and
moving this –OH substitution to the meta position (compounds 20 vs 21) relieves this
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interference. This steric interference in the inhibitory activity is again revealed when the
activities of compounds 17 and 22 pair or 18 and 14 pair is compared. Comparison of
activities of compounds 17 and 18 (Fig. 2) reveal that benzothiazole ring contributes better
inhibition of the protease than thiazole ring at the R3 position. Moreover, compounds 17 and
22 have the same R3 group, the benzothiazole ring. However, in the R2 benzyl ring, the –OH
is preferred over –OBn in the ortho position in the compounds 17 vs 22 or without any
substitution as in compound 13.
In compounds 18 and 14, R3 group is the same, a thiazole ring, whereas in the R2 group, the
meta position is preferred for the benzyloxy substitution than the ortho position or even –
OH substitution at the ortho position (Compound B). The benzyloxy group is flexible and
can be freely rotated along the oxygen-carbon single bond. The butterfly-shaped molecule
can interact with the protease residues by π-π interactions. In addition, the benzyloxy group
provides an extra aromatic ring to interact with the protease residues.
Substitution of the R2 benzyl ring with a pyridyl ring contributed to a significant reduction
of inhibitory activity (Compounds 23 vs 25), whereas with a furan ring did not affect the
activity (Compounds 23 and 24). Comparison of activities of compounds 18 and 19 reveals
that both have –OBn substitution in the ortho position of the R2 benzyl ring except that the
compound 19 has a –CH3 group substitution in the 8-HQ (R1) ring. This 8-HQ (R1)
substitution has a marginal contribution towards inhibition of the WNV protease activity.
3.2. Determination of IC50 values
Next, the IC50 values were determined for six compounds using the tri-peptide substrate and
concentrations of the inhibitor between zero and 40 μM (Table 1). The IC50 determinations
for the compounds 14 and B are shown in Fig. 3. The compound B (Ki = 3.4 ± 0.6 μM)
described in a previous study (Mueller et al., 2008) was used for validation of the IC50
values of unknown compounds analyzed in this study. The RFU values were converted into
% inhibition and plotted versus the Log10 of compound concentrations resulting in sigmoid
concentration-response curves. Under the conditions of our assay when the enzyme
concentration is less than the inhibitor concentration and the Ki value, the apparent IC50
value should not change with different enzyme concentrations, especially when the mode of
inhibition is competitive. Therefore, we determined the apparent IC50 values at two different
concentrations, 27 nM and 13.5 nM, of WNV NS2B/NS3pro to validate this expectation.
For tight binding inhibitors, the apparent value will simply be close to half of the
concentration of the enzyme which is not the case with compound 14. The IC50 values
determined at two different enzyme concentrations, 27 and 13.5 nM, were 1.16 and 1.21μM,
respectively. The experiment was repeated 4 times and the values ranged from 0.78 to 1.7
μM. The results of one representative experiment are shown in Fig. 3B. Moreover, at high
inhibitor concentrations, both curves reached a minimum RFU level, the same value (~300
RFU) as for the background control with no protease. The IC50 values were also determined
using the tetra-peptide substrate, Bz-Nle-Lys-Arg-Arg-AMC, for compounds 13 and 23
(Table 1). From the IC50 values of these 8-HQ inhibitors, compound 14 was identified to be
the most potent inhibitor. Therefore, mode of inhibition study and molecular modeling were
performed with compound 14 (see below).
3.3. Kinetics of inhibition of WNV NS2B/NS3pro by compound 14
We sought to analyze the mode of inhibition of the WNV NS2B/NS3pro-catalyzed cleavage
of the tetra-peptide substrate by compound 14. We performed kinetic analysis to determine
the Km, kcat and Vmax values in the presence and absence of the inhibitor (compound 14) at
four different concentrations (Fig. 4A and Fig. 4B and Table 2). The highest inhibitor
concentration used was 5 μM to avoid potential nonspecific inhibition due to aggregation
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which could interfere with the kinetics of true inhibition (Jadhav et al., 2010). In Fig. 4C, for
each of the four inhibitor concentrations (0, 1, 2, and 5 μM), we followed the kinetics at 12
substrate concentrations (0,1, 2, 4, 6, 8, 10, 15, 20, 30, 40 and 50 μM). As shown in Table 2
and Fig. 4A and 4B, the apparent Michaelis-Menten constants (Kmapp) increased and the
kcat/Km decreased proportionally to the increase in inhibitor concentrations in the range of 0,
1.0, 2.0 and 5.0 μM. The corresponding kcat values were within ~5% variance (Table 2). The
results indicate that compound 14 at increasing concentrations reduced the affinity of the
enzyme for the substrate as is evident from the increase of Km values. This type of inhibition
is a characteristic feature of competitive mode of inhibition.
3.4. Molecular Docking
Crystal structure of the tetra-peptide substrate-based inhibitor bound to the WNV NS2B/
NS3pro was reported previously (Aleshin et al., 2007; Erbel et al., 2006). To understand
how the N1 of 8-HQ in compounds 14 and 22 may be important for inhibitory activity of
WNV protease we predicted the free energy of binding of compound 14 and 22 to the active
site of WNV NS2B/NS3pro by molecular docking. We compared the orientation posed by
molecular docking and predicted free energy of binding values using compounds that exhibit
similar (e.g., compound 22) or distinct inhibitor activities (e.g., compounds 18 and 26 in Fig
2). AutoDock Vina was used to dock compounds 14, 17, 18, 22 and 26 in the active site
bound by Bz-Nle-Lys-Arg-Arg-H in the crystal structure (PDB code 2FP7 (Erbel et al.,
2006) (Fig. 5A). All compounds were predicted to interact with the active site by
hydrophobic and polar contacts to the residues shown in Fig. 5. Although each compound
was predicted to bind to the active site with free energy of binding values of −6.7 kcal per
mol or lower, compounds that exhibited greater than 75 % inhibition of protease activity,
including compounds 14 and 22, were predicted to bind better (−8.0 kcal and −8.6 kcal per
mol for compound 14 and 22 shown in Fig. 5B and 5E, respectively). The benzothiazole
moiety of more active compounds 17 and 22 is predicted to form contacts with Asp75 at the
active site. This interaction is not present in the less active compound 18 which has a
thiazole moiety at this position (Fig. 5C and 5E, vs 5D).
Comparison of the orientation posed by molecular docking permits analysis of potential
interactions in the context of functional protease activity. Compound 22, a potent protease
inhibitor, and compound 26, a significantly less active inhibitor, are structurally nearly
identical and the predicted docking scores suggest that the overall interactions between the
compounds and the protease are likely to be similar. The difference in inhibition between the
compounds 22 and 26 may result from potential interactions with Ser135. Although they are
predicted to bind similarly to the active site, the N1 of 8-HQ in compound 22, Fig.5E, is
positioned in close proximity to the active site Ser135 (3.2 Å) with a potential to form a H
bond with OH of Ser135, in contrast to the less active compound 26 with a carbon at this
position (4.5 Å; see Fig 5F) which is close to the acceptable limit for a distance of van der
Waals contacts. Since a H bond at this position would not be possible as a contact point
between compound 26 and the active site, the naphthen-1-ol ring of compound 26 may
assume a different orientation in binding the WNV NS2B/NS3pro active site compared to
the more active compound 22. Solving the crystal structure of the WNV NS2B/NS3pro in
the presence of compounds 14 and 22 could reveal the mode of inhibition of WNV NS2B/
NS3pro by this class of compounds containing the 8-HQ scaffold.
In conclusion, our results reveal, (1) some potent inhibitors of WNV NS2B/NS3pro by
compounds belonging to the 8-HQ class, (2) the N1 of 8-HQ ring is important for inhibition
of protease activity, and (3) the mode of inhibition of this class of compounds is by
competing with the substrate binding to the active site. Further work to solve the structure of
the protease in complex with the inhibitor is necessary to gain insight into the precise
orientation of the compound in the active site.
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Figure 1. Structures of 8-HQ derivatives
A. The structures of sixteen compounds that were analyzed in this study are shown. B. The
general structure of the 8-HQ scaffold (R1) is shown containing various aryl substituents at
R2 and R3.
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Figure 2. Inhibition of WNV NS2B-NS3pro by 8-HQ derivatives
Aprotinin was used as a positive control (100%) and DMSO alone (2%) as a negative
control (no inhibitor). Compounds were used at a final concentration of 40 μM. (A) Eight
compounds decreased the protease activity by more than 70%. Error bars indicate standard
deviation of the means.
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Figure 3. A. Determination of IC50 for compounds 14 and B
The IC50 values were determined using the tri-peptide substrate as described under
Materials and Methods. The x-values are displayed as the log of compound concentration
(0–40 μM). The error bars represent standard deviation. The experiments in triplicate were
repeated 4 times, and the IC50 values were determined to be 1.06 ± 0.07 μM for compound
14 and 3.6 +/− 2.0 for compound B. B. The IC50 of compound 14 was determined at two
different WNV NS2B/NS3pro concentrations and tri-peptide as the substrate. The
experiments in triplicate were repeated 4 times. The values ranged from 0.78 to 1.7 μM. The
results from one representative experiment are shown.
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Figure 4. A. Inhibition of WNV NS2BH-NS3pro protease activity by compound 14
Initial reaction rates of cleavage of the tetra-peptide-AMC substrate catalyzed by WNV
NS2BH-NS3 protease (28 nM) in 200 mM Tris HCl (pH 9.5), 6.0 mM NaCl, 30 % glycerol
and 0.1 % CHAPS at 37 C were determined by varying the tetra-peptide substrate
concentrations in the range of 1, 2, 4, 6, 8, 10, 15, 20, 30, 40 and 50 μM at each
concentration of inhibitor fixed at 0 (solid circle), 1.0 μM (open circle), 2.0 μM (solid
triangle) and 5.0 μM (open triangle). The reactions were initiated by the addition of WNV
NS2BH/NS3pro protease and the fluorescence intensity at 460 nm was monitored with an
excitation at 380 nm. Reactions were less than 5% completion in all cases to maintain valid
steady-state measurements. The solid lines are fitted lines using the Michaelis-Menten
equation. B. Lineweaver-Burk plot of compound 14. The same experiments as described in
Fig. 4A were used to plot this graph. The concentrations of the inhibitors are 0 (solid circle),
1.0 μM (open circle), 2.0 μM (solid triangle) and 5.0 μM (open triangle), respectively. The
concentrations of tetra-peptide substrate are (4, 6, 8, 10, 15, 20, 30, 40 and 50 μM range).
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Figure 5. Molecular docking of compounds 14 and 26 onto WNV protease structure
The WNV protease crystal structure coordinates (PDB ID code 2FP7) were used for
molecular docking. AutoDock Vina was used to dock each compound in the active site
bound by Bz-Nle-Lys-Arg-Arg-H substrate-based inhibitor (Erbel et al., 2006). The solvent-
accessible surface of the protein is shown in color-coded atoms (white, carbon; red, oxygen;
blue, nitrogen). The catalytic triad (H51, D75, and S135) is shown as a green surface. A.
The structure of the Bz-Nle-Lys-Arg-Arg-H substrate-based inhibitor bound WNV NS2B-
NS3pro (Erbel et al., 2006). B. Compound 14 is shown in the orientation posed by molecular
docking. Compounds 17, 18, 22 and 26 are shown in panels C, D, E and F, respectively.
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Table 1
Kinetics parameters for the tetra-peptide substrate and compound 14 against WNV NS2BH-NS3pro at 37 °C
Inhibitors IC50 (μM)a Inhibitors IC50 (μM)a IC50 (μM)b
B 3.6 ± 2.0 13 2.60 ± 0.09 6.18 ± 0.27
10 13.4 ± 3.9 14 1.06 ± 0.07 2.01 ± 0.08
16 3.4 ± 0.8 23 9.85 ± 0.34 12.86 ± 0.54
a
Tri-peptide substrate Boc-GKR-AMC;
b
Tetra-peptide substrate Bz-Nle-KRR-AMC.
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Table 2
Kinetics parameters for the tetra-peptide substrate and compound 14 against WNV NS2BH-NS3pro at 37 °C
[Inhibitors] Km kcat kcat/Km
μM μM s−1 M−1·s−1
0 24.56 ± 1.43 0.061 ± 0.001 2486 ± 185
1 28.36 ± 0.85 0.059 ± 0.002 2080 ± 137
2 35.96 ± 1.70 0.059 ± 0.002 1641 ± 139
5 45.93 ± 1.08 0.058 ± 0.002 1263 ± 75
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